Imaging Characteristics of Local Recurrences After Stereotactic Body Radiation Therapy for Stage I Non-small Cell Lung Cancer: Evaluation of Mass-like Fibrosis

Overview

Journal Thorac Cancer

Specialties Oncology
Pulmonary Medicine

Date 2015 Aug 15

PMID 26273357

Citations 6

Authors

Shinya Hayashi

Hidekazu Tanaka

Hiroaki Hoshi

Affiliations

Soon will be listed here.

Abstract

Background: This study aimed to evaluate stereotactic body radiation therapy (SBRT) in patients with stage I non-small cell lung cancer (NSCLC) in terms of radiation-induced changes and computed tomography (CT) features of local recurrence by 18F-fluorodeoxyglucose positron emission tomography ((18)F-FDG-PET).

Methods: From January 2006 to December 2012, 81 patients with NSCLC received SBRT. Follow-up consisted of non-contrast enhanced CT scans performed before and every four months after SBRT. In addition, 18F-FDG-PET/CT was conducted before SBRT for each patient, and one year later for each case suspected of recurrence. The CT findings were classified into two categories: mass-like fibrosis and others. The mass-like fibrosis category was subdivided into two patterns: mass-like consolidation (with air bronchogram) and mass-like opacity.

Results: Six patients had histologically confirmed local recurrence, including 83% (5/6) with mass-like opacity pattern and one case of modified conventional pattern (P = 0.02). In contrast, the non-recurrent group exhibited only 7% (5/75) with mass-like opacity and 13% (10/75) with mass-like consolidation pattern. Five patients with local recurrence presented with the mass-like opacity pattern, compared with 33% of patients (5/15) from the non-recurrent group (P = 0.01) and showed an increase in maximum diameter at ≥12 months after SBRT. The recurrent group also had a significantly higher standardized uptake value (SUVmax) than the non-recurrent group (P < 0.001), with all values >5 (range: 5.7-25.4).

Conclusion: The following characteristics of mass-like fibrosis should be considered indicators of local recurrence after SBRT: opacity pattern, increasing maximum diameter, and SUVmax > 5.

Citing Articles

Relationship between Dose Prescription Methods and Local Control Rate in Stereotactic Body Radiotherapy for Early Stage Non-Small-Cell Lung Cancer: Systematic Review and Meta-Analysis.

Eriguchi T, Takeda A, Nemoto T, Tsurugai Y, Sanuki N, Tateishi Y Cancers (Basel). 2022; 14(15).

PMID: 35954478 PMC: 9367274. DOI: 10.3390/cancers14153815.

Evaluation of tumor response after stereotactic body radiation therapy for lung cancer: Role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography.

Alcantara P, Martinez B, Garcia-Esquinas M, Belaustegui L, Bustos A J Clin Transl Res. 2021; 6(4):155-167.

PMID: 33501386 PMC: 7821750.

The CT appearance pattern of radiation-induced lung injury and tumor recurrence after stereotactic body radiation therapy in early stage non-small cell lung cancer.

Li Q, Liu Y, Su B, Zhao H, Lin Q, Zhu Y Transl Lung Cancer Res. 2020; 9(3):713-721.

PMID: 32676333 PMC: 7354147. DOI: 10.21037/tlcr-20-609.

Radiological differential diagnosis between fibrosis and recurrence after stereotactic body radiation therapy (SBRT) in early stage non-small cell lung cancer (NSCLC).

Frakulli R, Salvi F, Balestrini D, Palombarini M, Akshija I, Cammelli S Transl Lung Cancer Res. 2018; 6(Suppl 1):S1-S7.

PMID: 29299403 PMC: 5750152. DOI: 10.21037/tlcr.2017.10.01.

Comparison of particle beam therapy and stereotactic body radiotherapy for early stage non-small cell lung cancer: A systematic review and hypothesis-generating meta-analysis.

Chi A, Chen H, Wen S, Yan H, Liao Z Radiother Oncol. 2017; 123(3):346-354.

PMID: 28545956 PMC: 5568119. DOI: 10.1016/j.radonc.2017.05.007.

References

Takeda A, Kunieda E, Fujii H, Yokosuka N, Aoki Y, Oooka Y . Evaluation for local failure by 18F-FDG PET/CT in comparison with CT findings after stereotactic body radiotherapy (SBRT) for localized non-small-cell lung cancer. Lung Cancer. 2012; 79(3):248-53. DOI: 10.1016/j.lungcan.2012.11.008. View

Nagata Y, Hiraoka M, Shibata T, Onishi H, Kokubo M, Karasawa K . Prospective Trial of Stereotactic Body Radiation Therapy for Both Operable and Inoperable T1N0M0 Non-Small Cell Lung Cancer: Japan Clinical Oncology Group Study JCOG0403. Int J Radiat Oncol Biol Phys. 2015; 93(5):989-96. DOI: 10.1016/j.ijrobp.2015.07.2278. View

Nagata Y, Takayama K, Matsuo Y, Norihisa Y, Mizowaki T, Sakamoto T . Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame. Int J Radiat Oncol Biol Phys. 2005; 63(5):1427-31. DOI: 10.1016/j.ijrobp.2005.05.034. View

Takeda A, Kunieda E, Takeda T, Tanaka M, Sanuki N, Fujii H . Possible misinterpretation of demarcated solid patterns of radiation fibrosis on CT scans as tumor recurrence in patients receiving hypofractionated stereotactic radiotherapy for lung cancer. Int J Radiat Oncol Biol Phys. 2007; 70(4):1057-65. DOI: 10.1016/j.ijrobp.2007.07.2383. View

Trovo M, Linda A, El Naqa I, Javidan-Nejad C, Bradley J . Early and late lung radiographic injury following stereotactic body radiation therapy (SBRT). Lung Cancer. 2009; 69(1):77-85. DOI: 10.1016/j.lungcan.2009.09.006. View

Matsuo Y, Nagata Y, Mizowaki T, Takayama K, Sakamoto T, Sakamoto M . Evaluation of mass-like consolidation after stereotactic body radiation therapy for lung tumors. Int J Clin Oncol. 2007; 12(5):356-62. DOI: 10.1007/s10147-007-0691-9. View

Linda A, Trovo M, Bradley J . Radiation injury of the lung after stereotactic body radiation therapy (SBRT) for lung cancer: a timeline and pattern of CT changes. Eur J Radiol. 2009; 79(1):147-54. DOI: 10.1016/j.ejrad.2009.10.029. View

Timmerman R, Paulus R, Galvin J, Michalski J, Straube W, Bradley J . Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA. 2010; 303(11):1070-6. PMC: 2907644. DOI: 10.1001/jama.2010.261. View

Nagata Y, Wulf J, Lax I, Timmerman R, Zimmermann F, Stojkovski I . Stereotactic radiotherapy of primary lung cancer and other targets: results of consultant meeting of the International Atomic Energy Agency. Int J Radiat Oncol Biol Phys. 2011; 79(3):660-9. DOI: 10.1016/j.ijrobp.2010.10.004. View

10.

Takeda T, Takeda A, Kunieda E, Ishizaka A, Takemasa K, Shimada K . Radiation injury after hypofractionated stereotactic radiotherapy for peripheral small lung tumors: serial changes on CT. AJR Am J Roentgenol. 2004; 182(5):1123-8. DOI: 10.2214/ajr.182.5.1821123. View

11.

Tarohda T, Ishiguro M, Hasegawa K, Kohda Y, Onishi H, Aoki T . The management of tumor motions in the stereotactic irradiation to lung cancer under the use of Abches to control active breathing. Med Phys. 2011; 38(7):4141-6. DOI: 10.1118/1.3604151. View

12.

Kato S, Nambu A, Onishi H, Saito A, Kuriyama K, Komiyama T . Computed tomography appearances of local recurrence after stereotactic body radiation therapy for stage I non-small-cell lung carcinoma. Jpn J Radiol. 2010; 28(4):259-65. DOI: 10.1007/s11604-009-0415-3. View

13.

Nakajima N, Sugawara Y, Kataoka M, Hamamoto Y, Ochi T, Sakai S . Differentiation of tumor recurrence from radiation-induced pulmonary fibrosis after stereotactic ablative radiotherapy for lung cancer: characterization of 18F-FDG PET/CT findings. Ann Nucl Med. 2013; 27(3):261-70. DOI: 10.1007/s12149-012-0682-4. View

14.

Baumann P, Nyman J, Hoyer M, Wennberg B, Gagliardi G, Lax I . Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy. J Clin Oncol. 2009; 27(20):3290-6. DOI: 10.1200/JCO.2008.21.5681. View

15.

Huang K, Dahele M, Senan S, Guckenberger M, Rodrigues G, Ward A . Radiographic changes after lung stereotactic ablative radiotherapy (SABR)--can we distinguish recurrence from fibrosis? A systematic review of the literature. Radiother Oncol. 2012; 102(3):335-42. DOI: 10.1016/j.radonc.2011.12.018. View

16.

Israel O, Kuten A . Early detection of cancer recurrence: 18F-FDG PET/CT can make a difference in diagnosis and patient care. J Nucl Med. 2007; 48 Suppl 1:28S-35S. View

17.

Onishi H, Shirato H, Nagata Y, Hiraoka M, Fujino M, Gomi K . Stereotactic body radiotherapy (SBRT) for operable stage I non-small-cell lung cancer: can SBRT be comparable to surgery?. Int J Radiat Oncol Biol Phys. 2010; 81(5):1352-8. DOI: 10.1016/j.ijrobp.2009.07.1751. View

18.

Senthi S, Lagerwaard F, Haasbeek C, Slotman B, Senan S . Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis. Lancet Oncol. 2012; 13(8):802-9. DOI: 10.1016/S1470-2045(12)70242-5. View

19.

Kimura T, Matsuura K, Murakami Y, Hashimoto Y, Kenjo M, Kaneyasu Y . CT appearance of radiation injury of the lung and clinical symptoms after stereotactic body radiation therapy (SBRT) for lung cancers: are patients with pulmonary emphysema also candidates for SBRT for lung cancers?. Int J Radiat Oncol Biol Phys. 2006; 66(2):483-91. DOI: 10.1016/j.ijrobp.2006.05.008. View

20.

Dahele M, Palma D, Lagerwaard F, Slotman B, Senan S . Radiological changes after stereotactic radiotherapy for stage I lung cancer. J Thorac Oncol. 2011; 6(7):1221-8. DOI: 10.1097/JTO.0b013e318219aac5. View